By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > MAO inhibitor > Tranylcypromine

Tranylcypromine

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
4 Min Read
SHARE
3 min read|545 words

Tranylcypromine Drug Profile

What is Tranylcypromine?

Tranylcypromine is a prescription antidepressant medication that belongs to a class of drugs called monoamine oxidase inhibitors (MAOIs). It is primarily used to treat major depressive disorder, particularly in patients who have not responded adequately to other antidepressant treatments. This medication requires careful monitoring due to its potential for serious drug and food interactions.

Uses

Tranylcypromine is approved and used for several conditions:

  • Major depressive disorder: Primary indication for treatment-resistant depression when other antidepressants have failed
  • Atypical depression: Particularly effective for depression characterized by mood reactivity, increased appetite, and hypersomnia
  • Panic disorder: Sometimes prescribed off-label when first-line treatments are ineffective
  • Social anxiety disorder: Used in select cases where other medications have not provided adequate relief
  • Bipolar depression: Occasionally used as an adjunct treatment in treatment-resistant cases

How it works

Tranylcypromine works by inhibiting monoamine oxidase enzymes (MAO-A and MAO-B), which are responsible for breaking down neurotransmitters like serotonin, norepinephrine, and dopamine in the brain. By blocking these enzymes, the medication increases the levels of these mood-regulating chemicals, which can help alleviate symptoms of depression. The therapeutic effects typically take several weeks to become apparent.

Side effects

Common side effects:

Submit Your Paper
GMJ_Submit_Banner
  • Dizziness and lightheadedness
  • Dry mouth
  • Insomnia or sleep disturbances
  • Constipation
  • Blurred vision
  • Weight gain
  • Sexual dysfunction
  • Fatigue or weakness

Serious side effects requiring immediate medical attention:

  • Severe headache (may indicate hypertensive crisis)
  • Chest pain or rapid heartbeat
  • Severe nausea and vomiting
  • Stiff neck or neck pain
  • Sudden severe increase in blood pressure

Warnings and precautions

  • Hypertensive crisis risk: Can cause dangerous blood pressure spikes when combined with certain foods containing tyramine or specific medications
  • Dietary restrictions required: Patients must avoid aged cheeses, cured meats, fermented foods, and certain alcoholic beverages
  • Pregnancy considerations: Should only be used during pregnancy if potential benefits outweigh risks; not recommended during breastfeeding
  • Cardiovascular conditions: Use with extreme caution in patients with heart disease, high blood pressure, or cerebrovascular disease
  • Surgical procedures: Must be discontinued at least 10 days before elective surgery due to anesthetic interactions

Interactions

Tranylcypromine has numerous serious drug interactions:

  • SSRIs and SNRIs: Can cause serotonin syndrome; requires 2-5 week washout period between medications
  • Tricyclic antidepressants: May lead to severe hypertension and hyperthermia
  • Sympathomimetics: Including decongestants and stimulants, can cause dangerous blood pressure elevation
  • Opioid pain medications: Particularly meperidine, can cause severe and potentially fatal reactions
  • Tyramine-rich foods: Aged cheeses, wine, beer, and fermented foods can trigger hypertensive crisis
  • Over-the-counter cold medications: Many contain ingredients that can interact dangerously
  • Dietary supplements: St. John’s wort, 5-HTP, and tryptophan should be avoided
  • Local anesthetics: Epinephrine-containing anesthetics can cause severe blood pressure changes

Check interactions with the GMJ Interaction Checker

Dosage

Adult dosages for depression typically start at 10 mg twice daily, with gradual increases as tolerated. The usual effective dose ranges from 20-30 mg daily, divided into 2-3 doses. Maximum recommended dose is generally 60 mg daily. Dosage adjustments should be made slowly, typically at intervals of 1-3 weeks. Treatment should always be initiated and monitored by a healthcare provider experienced with MAOI medications. Discontinuation should be gradual to avoid withdrawal symptoms.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Tranylcypromine." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/tranylcypromine/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
How Brew Time Transforms Tea Chemistry: What Science Reveals About Steeping Duration

Research mapping tea extraction kinetics reveals that steeping duration fundamentally alters the…

The Case for ‘Health Care’: Why Language Precision Matters in Medical Journalism

STAT News's recent reader poll found that approximately 60% of respondents prefer…

UK Public Health Laboratory in Birmingham Releases Updated User Handbook for NHS Services

The UK Health Security Agency has released an updated user handbook for…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Phenelzine

By
Prof. Giorgi Pkhakadze
02/06/2026

Isocarboxazid

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up